Emergency Department, Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, China.
Emergency Department, Shantou Central Hospital, Shantou, Guangdong, China.
Am J Emerg Med. 2024 Apr;78:157-162. doi: 10.1016/j.ajem.2024.01.035. Epub 2024 Jan 23.
Paroxysmal supraventricular tachycardia (PSVT) is an arrhythmia commonly seen in the emergency department. Both modified Valsalva maneuver (MVM) and intravenous adenosine are the first line treatment, of which the former has e lower success rate while the latter has a higher success rate but some risks and adverse effects. Given both of these reverse rhythms quickly, combining them may achieve a better effect.
The objective of this study is to evaluate the success rate and potential risk of combining the use of intravenous adenosine while patients were doing MVM as a treatment for paroxysmal supraventricular tachycardia(pSVT).
DESIGN, SETTINGS AND PARTICIPANTS: We recruited patients with pSVT from 2017 to 2022, and randomly assigned them into 3 groups, MVM group, intravenous adenosine group, and combination therapy group, in which MVM was allowed to be performed twice, while intravenous adenosine was given in a titration manner to repeat three times, recorded the success rate and side effects in each group.
The success rate of the MVM group, adenosine group, and combination group are 42.11%, 75.00 and 86.11%, respectively. The success rate of the adenosine group and combination group is significantly higher than the n MVSM group (p < 0.01, p < 0.001), while the success rate of the combination group is higher than the adenosine group, it has no significant difference (p = 0.340). In terms of safety, the longest RR durations (asystole period) are 1.61 s, 1.60s, and 2.27 s, there is a statistical difference among the three groups (p < 0.01) and between the adenosine and combination group (0.018).
Therefore, we can conclude that combination therapy has a relatively high success rate and good safety profile, but the current study failed to show its superiority to adenosine.
阵发性室上性心动过速(PSVT)是急诊科常见的心律失常。改良瓦氏动作(MVM)和静脉注射腺苷都是一线治疗方法,前者成功率较低,后者成功率较高但存在一些风险和不良反应。鉴于这两种方法都能使节律逆转,将两者结合使用可能会取得更好的效果。
本研究旨在评估在患者行 MVM 的同时联合使用静脉注射腺苷治疗阵发性室上性心动过速(PSVT)的成功率和潜在风险。
设计、地点和参与者:我们从 2017 年至 2022 年招募了 PSVT 患者,并将其随机分为 MVM 组、腺苷组和联合治疗组。允许 MVM 重复进行两次,而腺苷则以滴定方式重复给予三次,记录每组的成功率和不良反应。
MVM 组、腺苷组和联合组的成功率分别为 42.11%、75.00%和 86.11%。腺苷组和联合组的成功率明显高于 MVM 组(p<0.01,p<0.001),而联合组的成功率高于腺苷组,但无统计学差异(p=0.340)。在安全性方面,最长 RR 间期(停搏期)分别为 1.61s、1.60s 和 2.27s,三组间存在统计学差异(p<0.01),且腺苷组和联合组间也存在统计学差异(0.018)。
因此,我们可以得出结论,联合治疗具有相对较高的成功率和良好的安全性,但本研究未能显示其优于腺苷。